Independent Power Producers
Compare Stocks
5 / 10Stock Comparison
VST vs NRG vs CEG vs GEN vs DYN
Revenue, margins, valuation, and 5-year total return — side by side.
Independent Power Producers
Renewable Utilities
Software - Infrastructure
Biotechnology
VST vs NRG vs CEG vs GEN vs DYN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Independent Power Producers | Independent Power Producers | Renewable Utilities | Software - Infrastructure | Biotechnology |
| Market Cap | $54.30B | $29.97B | $100.08B | $12.16B | $2.88B |
| Revenue (TTM) | $16.73B | $30.71B | $25.53B | $4.73B | $0.00 |
| Net Income (TTM) | $944M | $864M | $2.32B | $603M | $-446M |
| Gross Margin | 15.9% | 21.8% | 75.8% | 77.7% | — |
| Operating Margin | 5.8% | 6.0% | 12.1% | 36.9% | — |
| Forward P/E | 18.7x | 17.2x | 27.6x | 7.7x | — |
| Total Debt | $20.39B | $16.62B | $8.99B | $8.31B | $20M |
| Cash & Equiv. | $816M | $260M | $3.75B | $1.01B | $893M |
VST vs NRG vs CEG vs GEN vs DYN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jan 22 | May 26 | Return |
|---|---|---|---|
| Vistra Corp. (VST) | 100 | 735.4 | +635.4% |
| NRG Energy, Inc. (NRG) | 100 | 394.3 | +294.3% |
| Constellation Energ… (CEG) | 100 | 667.5 | +567.5% |
| Gen Digital Inc. (GEN) | 100 | 75.8 | -24.2% |
| Dyne Therapeutics, … (DYN) | 100 | 235.4 | +135.4% |
Price return only. Dividends and distributions are not included.
Quick Verdict: VST vs NRG vs CEG vs GEN vs DYN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
VST ranks third and is worth considering specifically for long-term compounding.
- 9.8% 10Y total return vs NRG's 10.3%
- 0.6% yield, 6-year raise streak, vs GEN's 2.5%, (2 stocks pay no dividend)
NRG is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 9.2%, EPS growth -18.0%, 3Y rev CAGR -0.9%
- 9.2% revenue growth vs DYN's -40.7%
- 332.3% ROA vs DYN's -50.9%, ROIC 9.1% vs -221.2%
CEG is the clearest fit if your priority is sleep-well-at-night and valuation efficiency.
- Lower volatility, beta 1.44, Low D/E 60.5%, current ratio 1.53x
- PEG 0.85 vs GEN's 2.83
GEN carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 0 yrs, beta 0.98, yield 2.5%
- Beta 0.98, yield 2.5%, current ratio 0.51x
- Better valuation composite
- 12.8% margin vs DYN's 2.0%
DYN is the clearest fit if your priority is momentum.
- +47.7% vs GEN's -21.6%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 9.2% revenue growth vs DYN's -40.7% | |
| Value | Better valuation composite | |
| Quality / Margins | 12.8% margin vs DYN's 2.0% | |
| Stability / Safety | Beta 0.98 vs DYN's 2.34 | |
| Dividends | 0.6% yield, 6-year raise streak, vs GEN's 2.5%, (2 stocks pay no dividend) | |
| Momentum (1Y) | +47.7% vs GEN's -21.6% | |
| Efficiency (ROA) | 332.3% ROA vs DYN's -50.9%, ROIC 9.1% vs -221.2% |
VST vs NRG vs CEG vs GEN vs DYN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
VST vs NRG vs CEG vs GEN vs DYN — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
GEN leads in 2 of 6 categories
VST leads 1 • NRG leads 0 • CEG leads 0 • DYN leads 0 • 3 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
GEN leads this category, winning 6 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NRG and DYN operate at a comparable scale, with $30.7B and $0 in trailing revenue. GEN is the more profitable business, keeping 12.8% of every revenue dollar as net income compared to NRG's 2.8%. On growth, GEN holds the edge at +25.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $16.7B | $30.7B | $25.5B | $4.7B | $0 |
| EBITDAEarnings before interest/tax | $4.0B | $3.8B | $4.7B | $2.2B | -$466M |
| Net IncomeAfter-tax profit | $944M | $864M | $2.3B | $603M | -$446M |
| Free Cash FlowCash after capex | $640M | $196M | $1.3B | $1.5B | -$424M |
| Gross MarginGross profit ÷ Revenue | +15.9% | +21.8% | +75.8% | +77.7% | — |
| Operating MarginEBIT ÷ Revenue | +5.8% | +6.0% | +12.1% | +36.9% | — |
| Net MarginNet income ÷ Revenue | +5.6% | +2.8% | +9.1% | +12.8% | — |
| FCF MarginFCF ÷ Revenue | +3.8% | +0.6% | +5.0% | +32.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -68.2% | +13.7% | +1.4% | +25.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | -51.3% | -86.3% | -49.1% | +19.2% | +13.6% |
Valuation Metrics
GEN leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 19.1x trailing earnings, GEN trades at a 74% valuation discount to VST's 72.6x P/E. Adjusting for growth (PEG ratio), CEG offers better value at 1.33x vs GEN's 7.00x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $54.3B | $30.0B | $100.1B | $12.2B | $2.9B |
| Enterprise ValueMkt cap + debt − cash | $73.9B | $46.3B | $105.3B | $19.5B | $2.0B |
| Trailing P/EPrice ÷ TTM EPS | 72.57x | 38.49x | 43.30x | 19.14x | -5.03x |
| Forward P/EPrice ÷ next-FY EPS est. | 18.69x | 17.17x | 27.62x | 7.73x | — |
| PEG RatioP/E ÷ EPS growth rate | 6.48x | 2.64x | 1.33x | 7.00x | — |
| EV / EBITDAEnterprise value multiple | 17.24x | 12.18x | 25.87x | 9.60x | — |
| Price / SalesMarket cap ÷ Revenue | 3.20x | 0.98x | 3.92x | 3.09x | — |
| Price / BookPrice ÷ Book value/share | 10.66x | 19.78x | 6.77x | 5.42x | 2.31x |
| Price / FCFMarket cap ÷ FCF | 420.90x | 39.13x | 77.71x | 10.08x | — |
Profitability & Efficiency
Evenly matched — NRG and DYN each lead in 3 of 9 comparable metrics.
Profitability & Efficiency
NRG delivers a 51.4% return on equity — every $100 of shareholder capital generates $51 in annual profit, vs $-61 for DYN. DYN carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to NRG's 9.89x. On the Piotroski fundamental quality scale (0–9), GEN scores 8/9 vs DYN's 4/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +18.9% | +51.4% | +15.6% | +25.9% | -61.5% |
| ROA (TTM)Return on assets | +2.4% | +3.3% | +4.1% | +3.8% | -50.9% |
| ROICReturn on invested capital | +4.3% | +9.1% | +11.9% | +12.4% | -2.2% |
| ROCEReturn on capital employed | +4.5% | +49.7% | +6.5% | +12.5% | -52.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 7 | 7 | 8 | 4 |
| Debt / EquityFinancial leverage | 3.99x | 9.89x | 0.61x | 3.66x | 0.02x |
| Net DebtTotal debt minus cash | $19.6B | $16.4B | $5.2B | $7.3B | -$873M |
| Cash & Equiv.Liquid assets | $816M | $260M | $3.7B | $1.0B | $893M |
| Total DebtShort + long-term debt | $20.4B | $16.6B | $9.0B | $8.3B | $20M |
| Interest CoverageEBIT ÷ Interest expense | 1.95x | 2.40x | 6.04x | 2.97x | -71.06x |
Total Returns (Dividends Reinvested)
VST leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in VST five years ago would be worth $101,093 today (with dividends reinvested), compared to $9,815 for DYN. Over the past 12 months, DYN leads with a +47.7% total return vs GEN's -21.6%. The 3-year compound annual growth rate (CAGR) favors VST at 90.9% vs GEN's 7.3% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -2.8% | -4.7% | -12.4% | -23.9% | -5.6% |
| 1-Year ReturnPast 12 months | +15.2% | +37.0% | +29.7% | -21.6% | +47.7% |
| 3-Year ReturnCumulative with dividends | +596.0% | +419.6% | +308.4% | +23.7% | +25.1% |
| 5-Year ReturnCumulative with dividends | +910.9% | +373.2% | +675.0% | +4.6% | -1.9% |
| 10-Year ReturnCumulative with dividends | +983.1% | +1027.9% | +675.0% | +116.9% | -26.9% |
| CAGR (3Y)Annualised 3-year return | +90.9% | +73.2% | +59.8% | +7.3% | +7.7% |
Risk & Volatility
Evenly matched — NRG and GEN each lead in 1 of 2 comparable metrics.
Risk & Volatility
GEN is the less volatile stock with a 0.98 beta — it tends to amplify market swings less than DYN's 2.34 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NRG currently trades 82.9% from its 52-week high vs GEN's 61.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.56x | 1.84x | 1.44x | 0.98x | 2.34x |
| 52-Week HighHighest price in past year | $219.82 | $189.96 | $412.70 | $32.22 | $25.00 |
| 52-Week LowLowest price in past year | $133.73 | $114.00 | $241.46 | $17.78 | $8.06 |
| % of 52W HighCurrent price vs 52-week peak | +73.0% | +82.9% | +77.6% | +61.2% | +69.9% |
| RSI (14)Momentum oscillator 0–100 | 52.2 | 48.0 | 60.1 | 50.3 | 44.5 |
| Avg Volume (50D)Average daily shares traded | 4.0M | 2.8M | 2.8M | 6.2M | 2.0M |
Analyst Outlook
Evenly matched — NRG and GEN each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: VST as "Buy", NRG as "Buy", CEG as "Buy", GEN as "Buy", DYN as "Buy". Consensus price targets imply 115.2% upside for DYN (target: $38) vs 23.2% for NRG (target: $194). For income investors, GEN offers the higher dividend yield at 2.54% vs CEG's 0.48%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $227.60 | $194.00 | $405.33 | $32.00 | $37.60 |
| # AnalystsCovering analysts | 21 | 26 | 19 | 21 | 13 |
| Dividend YieldAnnual dividend ÷ price | +0.6% | — | +0.5% | +2.5% | — |
| Dividend StreakConsecutive years of raises | 6 | 7 | 3 | 0 | — |
| Dividend / ShareAnnual DPS | $0.90 | — | $1.55 | $0.50 | — |
| Buyback YieldShare repurchases ÷ mkt cap | +1.9% | 0.0% | +0.4% | +2.2% | 0.0% |
GEN leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). VST leads in 1 (Total Returns). 3 tied.
VST vs NRG vs CEG vs GEN vs DYN: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is VST or NRG or CEG or GEN or DYN a better buy right now?
For growth investors, NRG Energy, Inc.
(NRG) is the stronger pick with 9. 2% revenue growth year-over-year, versus -12. 4% for Vistra Corp. (VST). Gen Digital Inc. (GEN) offers the better valuation at 19. 1x trailing P/E (7. 7x forward), making it the more compelling value choice. Analysts rate Vistra Corp. (VST) a "Buy" — based on 21 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — VST or NRG or CEG or GEN or DYN?
On trailing P/E, Gen Digital Inc.
(GEN) is the cheapest at 19. 1x versus Vistra Corp. at 72. 6x. On forward P/E, Gen Digital Inc. is actually cheaper at 7. 7x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Constellation Energy Corporation wins at 0. 85x versus Gen Digital Inc. 's 2. 83x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — VST or NRG or CEG or GEN or DYN?
Over the past 5 years, Vistra Corp.
(VST) delivered a total return of +910. 9%, compared to -1. 9% for Dyne Therapeutics, Inc. (DYN). Over 10 years, the gap is even starker: NRG returned +1028% versus DYN's -26. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — VST or NRG or CEG or GEN or DYN?
By beta (market sensitivity over 5 years), Gen Digital Inc.
(GEN) is the lower-risk stock at 0. 98β versus Dyne Therapeutics, Inc. 's 2. 34β — meaning DYN is approximately 139% more volatile than GEN relative to the S&P 500. On balance sheet safety, Dyne Therapeutics, Inc. (DYN) carries a lower debt/equity ratio of 2% versus 10% for NRG Energy, Inc. — giving it more financial flexibility in a downturn.
05Which is growing faster — VST or NRG or CEG or GEN or DYN?
By revenue growth (latest reported year), NRG Energy, Inc.
(NRG) is pulling ahead at 9. 2% versus -12. 4% for Vistra Corp. (VST). On earnings-per-share growth, the picture is similar: Gen Digital Inc. grew EPS 8. 4% year-over-year, compared to -68. 4% for Vistra Corp.. Over a 3-year CAGR, GEN leads at 12. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — VST or NRG or CEG or GEN or DYN?
Gen Digital Inc.
(GEN) is the more profitable company, earning 16. 3% net margin versus 0. 0% for Dyne Therapeutics, Inc. — meaning it keeps 16. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GEN leads at 40. 9% versus 0. 0% for DYN. At the gross margin level — before operating expenses — GEN leads at 80. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is VST or NRG or CEG or GEN or DYN more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Constellation Energy Corporation (CEG) is the more undervalued stock at a PEG of 0. 85x versus Gen Digital Inc. 's 2. 83x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Gen Digital Inc. (GEN) trades at 7. 7x forward P/E versus 27. 6x for Constellation Energy Corporation — 19. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DYN: 115. 2% to $37. 60.
08Which pays a better dividend — VST or NRG or CEG or GEN or DYN?
In this comparison, GEN (2.
5% yield), VST (0. 6% yield), CEG (0. 5% yield) pay a dividend. NRG, DYN do not pay a meaningful dividend and should not be held primarily for income.
09Is VST or NRG or CEG or GEN or DYN better for a retirement portfolio?
For long-horizon retirement investors, Vistra Corp.
(VST) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (0. 6% yield, +983. 1% 10Y return). Dyne Therapeutics, Inc. (DYN) carries a higher beta of 2. 34 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (VST: +983. 1%, DYN: -26. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between VST and NRG and CEG and GEN and DYN?
These companies operate in different sectors (VST (Utilities) and NRG (Utilities) and CEG (Utilities) and GEN (Technology) and DYN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
VST, GEN pay a dividend while NRG, CEG, DYN do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.